Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.
An expert analyst thinks Arcus Biosciences' medicine could make more money than expected, so they raised their price guess by one-third. When smart analysts feel more hopeful about a company's future earnings, it's worth noticing—but it doesn't mean the stock will definitely go up.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.